Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action.
Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, Eremin SR, Bolan G, Unemo M. · 2017
Read Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. by Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, Eremin SR, Bolan G, Unemo M. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5501266.txt.
Description
Wi and co-authors present a Policy Forum article in PLoS Medicine on drug resistance in gonorrhea. The bacterium Neisseria gonorrhoeae causes about 78 million adult cases a year, by WHO counts. Resistance has defeated drug class after drug class. Ceftriaxone now stands as the last reliable single treatment in most countries. Failures against it have already appeared.
The authors describe the WHO global surveillance program for gonococcal resistance. Its lab network tracks trends and guides treatment rules. Stronger joint action is urged on prevention, partner care, and failure checks. Rapid bedside tests that also predict resistance are a key need. New drugs and a vaccine remain the lasting fix, they argue.
Catalog record
| CREATOR | Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, Eremin SR, Bolan G, Unemo M. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |